# Frank Yu

> Frank Yu is a venture - series unknown investor at Ally Bridge Group backing Health Care. See 23 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ally Bridge Group](https://shizune.co/investors/profile/ally-bridge-group)
- Total investments: 23
- Last investment: Aug 2025
- Lead investor: 70%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/frank-yu-4649ab55

Frank Yu is a venture - series unknown investor at Ally Bridge Group focused on Health Care and Biotechnology. Frank Yu - Founder and CEO @ Ally Bridge Group

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 10 | 43% |
| Biotechnology | 9 | 39% |
| Medical | 5 | 22% |
| Medical Device | 5 | 22% |
| Therapeutics | 4 | 17% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 4 | 17% |
| Series B | 3 | 13% |
| Funding Round | 3 | 13% |
| Series A | 2 | 9% |
| Series C | 2 | 9% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 13 | 57% |
| France | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Mission Bio | Mission Bio delivers targeted solutions for high-impact applications with the Tapestri Platform. The Tapestri Platform is the industry’s first and only single-cell multi-omics platform, enabling genotype and phenotype from the same cell and precise detection of heterogeneity in disease progression and treatment response. Application areas includeoncology blood cancers, solid tumors, and genome editing validation. |  | Venture - Series Unknown | Aug 05, 2025 |  |
| Arbor Biotechnologies | Arbor Biotechnologies is a biotechnology company specializing in next-generation gene editing therapeutics to treat genetic diseases. The company utilizes artificial intelligence and high-throughput screening to discover and optimize novel gene-editing systems. Its research focuses on expanding the CRISPR-based gene editing toolbox for therapeuticapplications. Arbor aims to develop treatments for rare and complex diseases by engineering precise and efficient genetic modifications. | $73.9M | Series C | Mar 18, 2025 |  |
| Aerin Medical | Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing. Its device utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion, enabling patients suffering from nasal breathing disorders to open their nasal airway quickly, safely, andeffectively. | $32.5M |  | Jan 13, 2025 |  |
| Imperative Care | Imperative Care focuses on developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. It focuses on medical technology designed to expedite and improve the effectiveness of treatment, giving patients a chance for optimal recovery. | $150M | Series E | Jul 25, 2024 |  |
| RefleXion Medical | RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $105M |  | Nov 15, 2023 |  |
| Vida Health | Vida Health is a virtual care platform intentionally designed to treat a person’s whole health by treating mental and physical conditions, together. Vida’s clinically validated approach combines an AI-powered, personalized experience with the support and human connection of coaches and therapists. Vida’s app offers video sessions, messaging, anddigital content to help people prevent, manage, and reverse chronic conditions — like obesity, diabetes and hypertension — and the mental conditions that accompany them — like stress, depression, and anxiety. Some of America’s largest employers and health plans trust Vida’s whole health offering.The company was founded in 2014 and is based in San Francisco, California | $28.5M |  | Nov 09, 2023 |  |
| Syapse | To achieve more precise care for every patient, we need to transform real-world evidence into insights that can directly impact care. At Syapse, that is real-world care. It’s found in the way we empower healthcare organizations to work together in active, transparent partnerships, delivering complete patient insights to answer the questions thatmatter and then purposefully applying it at where patients receive care – driving real impact for cancer patients and beyond. | $35M | Venture - Series Unknown | Jul 27, 2022 |  |
| Aerin Medical | Aerin Medical is a health technology company that develops therapeutic devices to improve nasal breathing. Its device utilizes low-power radiofrequency energy to remodel nasal soft tissues and address the underlying cause of nasal congestion, enabling patients suffering from nasal breathing disorders to open their nasal airway quickly, safely, andeffectively. | $60M | Private Equity | Jun 16, 2022 |  |
| RefleXion Medical | RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $80M |  | Mar 10, 2022 |  |
| RefleXion Medical | RefleXion is developing the first biology-guided radiotherapy system, a significant change in strategy from single tumor therapy to the ability to one day treat multiple tumors in the same treatment session in cancers that have metastasized. Currently, the RefleXion X1 machine is cleared for the delivery of stereotactic body radiotherapy (SBRT),stereotactic radiosurgery (SRS) and intensity modulated radiotherapy (IMRT). The company is also developing BgRT, which incorporates positron-emission tomography (PET) imaging data to enable tumors to continuously signal their location. The BgRT technology will synchronize these data with the linear accelerator to direct radiotherapy to tumors with subsecond latency. | $80M | Series E | Mar 10, 2022 |  |

10 of 23 investments shown.

## Co-investors
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 5 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 4 deals together
- [General Atlantic](https://shizune.co/investors/profile/general-atlantic) — VC Fund, 4 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [Canvas Prime](https://shizune.co/investors/profile/canvas-venture-fund) — VC Fund, 3 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 3 deals together

## About Ally Bridge Group

VC Fund · Hong Kong, Hong Kong

Ally Bridge Group is a healthcare-focused investment group committed to venture and growth capital, buyout, and hedge fund investing. Ally Bridge Group focuses on both private and public equity investments, with a particular emphasis on pioneering life sciences companies and technologies. The firm is dedicated to bridging the gap betweengroundbreaking healthcare innovations and global markets. By leveraging its expertise and extensive network, Ally Bridge Group supports the growth and development of its portfolio companies. Its investment strategy is centered on transformative technologies and solutions that address major unmet medical needs.

5 contacts available at Ally Bridge Group.

| Name | Title | Profile |
| --- | --- | --- |
| Steven Plachtyna | Vice President | https://shizune.co/investors/profile/steven-plachtyn |
| Arthur Kuan | Founding Member | https://shizune.co/investors/profile/arthur-kuan |
| David Nikodem | Managing Director | https://shizune.co/investors/profile/david-nikodem |
| Dayu Teng | Venture Partner | https://shizune.co/investors/profile/dayu-teng |
| Frank Yu | Founder and CEO | https://shizune.co/investors/profile/frank-yu-3 |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Frank Yu invest in?

Frank Yu invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 23 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Frank Yu last invest?

The most recent investment recorded for Frank Yu closed in Aug 2025. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co